Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Rectal Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Trastuzumab 78Capecitabine 59Cyclophosphamide 54Paclitaxel 52Docetaxel 50Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 26exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Taxes 17Everolimus 17Epirubicin 15pertuzumab 13Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13palbociclib 12Magnetic Resonance Spectroscopy 12liposomal doxorubicin 11atezolizumab 11Filgrastim 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × Receptor Protein-Tyrosine Kinases × Clear all
NCT00677326 2009-12-29

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

Tokyo University

Phase 1/2 Terminated
1 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡